brexpiprazole , 10mMinDMSO , 913611-97-9
CAS NO.：913611-97-9
Empirical Formula: C25H27N3O2S
Molecular Weight: 433.57
MDL number: MFCD27987920
EINECS: 811-628-7
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB159.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 179 - 181oC |
| Boiling point: | 675.2±55.0 °C(Predicted) |
| Density | 1.245±0.06 g/cm3(Predicted) |
| storage temp. | Refrigerator |
| solubility | Dichloromethane (Slightly), Chloroform (Slightly), Methanol (Slightly) |
| pka | 11.22±0.70(Predicted) |
| form | Solid |
| color | White to Off-White |
| InChI | InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29) |
| InChIKey | ZKIAIYBUSXZPLP-UHFFFAOYSA-N |
| SMILES | N1C2=C(C=CC(OCCCCN3CCN(C4=C5C=CSC5=CC=C4)CC3)=C2)C=CC1=O |
Description and Uses
Brexpiprazole is a novel antipsychotic drug which serves as a serotonin ® dopamine activity modulator and has demonstrated efficacy as an adjunctive treatment in patients with major depressive disorder (MDD). The drug exhibits a unique pharmacological profile, acting as a partial agonist of serotonin 5-HT1A and dopamine D2 receptors and as a full antagonist of 5-HT2A and noradrenaline α1B/2C receptors, with similar subnanomolar binding affinity. The drug, which was developed by Otsuka and Lundbeck, was approved in 2015 by the FDA for the treatment of schizophrenia and as an adjunctive treatment for depression. Brexpiprazole is widely considered to be a successor to Otsuka’s antipsychotic drug aripiprazole (trade name Abilify) whose patent expired in August 2014.
Brexpiprazole is a kind of atypical antipsychotic. It is a dopamine D2 receptor partial agonist. As a novel serotonin-dopamine activity modulator, it can be used for the treatment of schizophrenia, and for the adjunctive treatment for depression. It can also provide efficacy and tolerability over established adjunctive treatments formajor depressive disorder(MDD).Recent study has also suggested it can ameliorate PCP-induced cognitive deficits in mice via 5-HT1A receptors.
Safety
| Symbol(GHS) |    GHS07,GHS08,GHS09 |
| Signal word | Danger |
| Hazard statements | H372-H400-H351-H362-H360-H302-H410 |
| Precautionary statements | P201-P202-P281-P308+P313-P405-P501-P260-P264-P270-P314-P501-P201-P260-P263-P264-P270-P308+P313-P273-P391-P501-P264-P270-P301+P312-P330-P501-P273-P391-P501 |
